Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jacintha Shenton"'
Autor:
Cris Kamperschroer, Jacintha Shenton, Hervé Lebrec, John K. Leighton, Paul A. Moore, Oliver Thomas
Publikováno v:
Journal of Immunotoxicology, Vol 17, Iss 1, Pp 67-85 (2020)
Currently, there is a multitude of CD3 bispecifics with different molecular designs and binding properties in preclinical and clinical development for the treatment of liquid or solid tumors. The key safety concerns with CD3 bispecifics are excessive
Externí odkaz:
https://doaj.org/article/9b9d19fabbc749bc85340c7759626998
Autor:
David Ackley, Joanne Birkebak, Jorg Blumel, Todd Bourcier, Christina de Zafra, Andrew Goodwin, Wendy Halpern, Danuta Herzyk, Sven Kronenberg, Robert Mauthe, Jacintha Shenton, Dana Shuey, Ronald L. Wange
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 138
The nonhuman primate (NHP) has always been a limited resource for pharmaceutical research with ongoing efforts to conserve. This is due to their inherent biological properties, the growth in biotherapeutics and other modalities, and their use in smal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5931fc33f2ffe38581252e72ca007cdc
https://pubmed.ncbi.nlm.nih.gov/36586472
https://pubmed.ncbi.nlm.nih.gov/36586472
Autor:
John Leighton, Jacintha Shenton, Paul A Moore, Oliver Thomas, Herve Lebrec, Cris Kamperschroer
Publikováno v:
Journal of Immunotoxicology, Vol 17, Iss 1, Pp 67-85 (2020)
Currently, there is a multitude of CD3 bispecifics with different molecular designs and binding properties in preclinical and clinical development for the treatment of liquid or solid tumors. The key safety concerns with CD3 bispecifics are excessive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce2ee2c651440cfde51cdc8de8d46cba
https://doi.org/10.1080/1547691x.2020.1729902
https://doi.org/10.1080/1547691x.2020.1729902
Autor:
Mathieu Marella, Xiang Yao, Vinicius Carreira, Marta F. Bustamante, H. Brent Clark, Carolyn C. Jackson, Enrique Zudaire, Jordan M. Schecter, Tynisha D. Glover, Jacintha Shenton, Ingrid Cornax
Publikováno v:
J Histochem Cytochem
B-cell maturation antigen (BCMA) is a target for the treatment of multiple myeloma with cytolytic therapies, such as chimeric antigen receptor T-cells or T-cell redirecting antibodies. To better understand the potential for “on-target/off-tumor”
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2aab657a4b23cf6ef58b8827699f46a
https://europepmc.org/articles/PMC8971684/
https://europepmc.org/articles/PMC8971684/
Autor:
Nataša Obermajer, Adam Zwolak, Kelly Van De Ven, Shana Versmissen, Aleksandra Brajic, Ted Petley, Dan Weinstock, Jason Aligo, Fang Yi, Stephen Jarantow, Keith Schutsky, Ken Tian, Angelilo Lorraine, Diana Alvarez Arias, Kristel Buyens, Vince Torti, Krista Menard, Katharine Rogers, Brian Geist, Marjolein Van Heerden, Gerald Chu, Bie Verbist, Maté Ongenaert, Julien Hasler, Kathryn Packman, Jacintha Shenton, Dirk Brehmer, Josh Lauring, Regina J. Brown, James Greger, Daphne Salick Ryan, Sanjaya Singh, Matthew V. Lorenzi, Laurie Lenox, Sylvie Laquerre
Publikováno v:
Cancer Research. 82:ND07-ND07
JNJ-78306358 is a first-in-class bispecific antibody (bsAb), engineered using the Zymeworks Azymetric™ platform, to treat advanced stage solid tumors. Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility class I molecule wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ec05d991c88124094370dfd690c7319
https://doi.org/10.1158/1538-7445.am2022-nd07
https://doi.org/10.1158/1538-7445.am2022-nd07
Autor:
Jacintha Shenton, Mark Collinge, Joshua Arrington, Darrell R. Boverhof, Wendy J. Freebern, Herve Lebrec, Daniel T. Mytych, Brigitte Molinier, Lei Zhou, Kristin L. Henson, Ronald L. Wange, Marie Soleil Christin-Piché, Hans D. Ochs, Yung Yang
Publikováno v:
Regulatory Toxicology and Pharmacology. 69:7-21
The T-cell-dependent antibody response (TDAR) assay is a measure of immune function that is dependent upon the effectiveness of multiple immune processes, including antigen uptake and presentation, T cell help, B cell activation, and antibody product
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7315045a36d2c566ee289463a46fa3ca
https://doi.org/10.1016/j.yrtph.2014.02.008
https://doi.org/10.1016/j.yrtph.2014.02.008
Autor:
Pascale Bellon-Gagnon, Genevieve S. Bondy, Virginia Liston, Monique Parenteau, Laurie Coady, David E. Lefebvre, Jacintha Shenton, Cheryl Armstrong, Michael Barker, Ivan Curran, Kathryn Rutherford, Rekha Mehta, Syed A. Aziz
Publikováno v:
Journal of Toxicology and Environmental Health, Part A. 71:1516-1525
Perfluorooctanesulfonate (PFOS) is a stable and environmentally persistent metabolic or degradation product of perfluorooctanyl compounds that were manufactured for a variety of industrial and consumer applications. PFOS itself was sold for use as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82c257539c81fabc90ec7e3544739e56
https://doi.org/10.1080/15287390802391943
https://doi.org/10.1080/15287390802391943
Autor:
Ralph Alderson, Jennifer R. Brown, Olivia Gardner, Liqin Liu, Weirong Wang, Imran Khan, Syd Johnson, Hua Li, Yu-Nien Sun, Xiling Jiang, Jeff Nordstrom, Jacintha Shenton, Pamela L. Clemens
Publikováno v:
Cancer Research. 77:4089-4089
Duvortuxizumab (also known as JNJ-64052781 and MGD011) is a bispecific CD19 x CD3 DART® molecule designed to simultaneously target CD19-positive cells for recognition and elimination by CD3-expressing T-lymphocytes as effector cells. Duvortuxizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4fe382f669ad354b19d389e90b89acd
https://doi.org/10.1158/1538-7445.am2017-4089
https://doi.org/10.1158/1538-7445.am2017-4089
Publikováno v:
Current opinion in pharmacology. 12(5)
Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7538283cf7a7b32f79996d4677b8c68c
https://pubmed.ncbi.nlm.nih.gov/22920732
https://pubmed.ncbi.nlm.nih.gov/22920732
Autor:
Gary J. Chellman, Joseph R Piccotti, Wendy J. Komocsar, Daniel Wierda, Thomas T. Kawabata, Leigh Ann Burns-Naas, Mark Collinge, Jacintha Shenton
Publikováno v:
Journal of immunotoxicology. 9(2)
The development and regulatory approval of immunomodulatory pharmaceuticals to treat many human diseases has increased significantly over the last two decades. As discussed by FDA and ICH guidelines, all human pharmaceuticals in development should be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58f2412809199ec3976a45ed83e4972c
https://pubmed.ncbi.nlm.nih.gov/22428536
https://pubmed.ncbi.nlm.nih.gov/22428536